Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Involvement of the Physician in Primary Prevention and Pre-hospital Management of Stroke (PREVENTION AVC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03975218
Recruitment Status : Recruiting
First Posted : June 5, 2019
Last Update Posted : June 17, 2019
Sponsor:
Information provided by (Responsible Party):
Groupe Hospitalier Paris Saint Joseph

Brief Summary:

Stroke is a growing disease. It is the first pathology responsible for acquired handicap, the second of dementia and the second cause of death in the world. In France, they are the leading cause of death in women and the third cause in men. Sequelae and disabilities also represent a significant financial cost for health insurance.

The early management of the treatment improves the patient's vital and functional prognosis. The ability of the patient to identify the signs of stroke requiring urgent consultation and proper orientation are therefore crucial for further management.

The most common signs that patients must recognize are muscle weakness or sudden paralysis of an arm, leg or half of the body, asymmetry of the face, tingling, numbness of a hemi-body, speech or understanding, loss of vision of an eye or hemifield, disorder of the coordination of a hemi-body. The variety of clinical pictures complicates primary prevention.

In this context, a 2010-2014 National Stroke Action Plan was undertaken with the aim, among other things, of developing information to prevent stroke and to limit its sequelae. In this plan, the attending physician must improve prevention in high-risk patients and be a link between the city and the hospital for follow-up.

Several questions arise:

  • Are patients who are regularly followed by a general practitioner better educated on the signs of stroke / TIA and thus more able to give an appropriate warning?
  • What is the profile of patients who have not been affected by the different modes of primary prevention?
  • What are the effective means of information and those desired

Condition or disease Intervention/treatment
Stroke Other: Patients With Stroke

Layout table for study information
Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Involvement of the Physician in Primary Prevention and Pre-hospital Management of Stroke
Actual Study Start Date : June 7, 2019
Estimated Primary Completion Date : March 14, 2020
Estimated Study Completion Date : September 14, 2020

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Patients with stroke
In addition to the usual care, the patient will have to complete a questionnaire analyzing the regularity of his follow-up by a physician.
Other: Patients With Stroke
In addition to the usual care, the patient will have to complete a questionnaire analyzing the regularity of his follow-up by a physician.




Primary Outcome Measures :
  1. Time until patient's care in the hospital after stroke's symptoms [ Time Frame: Day 1 ]
    The delay between the observation of signs of stroke and specialized neurovascular management at the hospital will be measured. This measures the impact of physician's prevention on the management of stroke.


Secondary Outcome Measures :
  1. Study the different effective means of primary prevention [ Time Frame: Day 1 ]
    Patient questionnaire corresponds to open question about physician in primary prevention and pre-hospital management of stroke to which the patient will respond yes or no.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patient hospitalized in the neurology / neurovascular department within the GHPSJ following a stroke (first episode or recurrence)
Criteria

Inclusion Criteria:

  • Patient whose age is ≥ 18 years
  • Patient hospitalized in the neurology / neurovascular department within the GHPSJ following a stroke (first episode or recurrence)
  • Francophone patient

Exclusion Criteria:

  • Patient with previously labeled cognitive impairment
  • Patient under tutorship or curatorship
  • Patient deprived of liberty
  • Patient unable to answer the questionnaire
  • Patient opposing participation in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03975218


Contacts
Layout table for location contacts
Contact: Marie BRUANDET, MD 0144127653 ext +33 mbruandet@hpsj.fr
Contact: Helene P BEAUSSIER, PharmD, PhD 0144127883 ext +33 crc@hpsj.fr

Locations
Layout table for location information
France
Groupe Hospitalier Paris Saint-Joseph Recruiting
Paris, France, 75014
Contact: Helene BEAUSSIER, PhD, PharmD    144127038    crc@hpsj.fr   
Sponsors and Collaborators
Groupe Hospitalier Paris Saint Joseph
Investigators
Layout table for investigator information
Principal Investigator: Marie BRUANDET, MD Groupe Hospitalier Paris Saint Joseph

Layout table for additonal information
Responsible Party: Groupe Hospitalier Paris Saint Joseph
ClinicalTrials.gov Identifier: NCT03975218     History of Changes
Other Study ID Numbers: PREVENTION AVC
First Posted: June 5, 2019    Key Record Dates
Last Update Posted: June 17, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Stroke
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases